Sigvotatug Vedotin

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against integrin beta-6 (IB6) conjugated, via a protease-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of sigvotatug vedotin targets and binds to IB6 on the surface of tumor cells. Following internalization, linker cleavage and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in IB6-expressing tumor cells. IB6 is overexpressed in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.

**Synonyms:** - Anti-integrin Beta-6 Antibody-drug Conjugate SGN-B6A - Anti-integrin Beta-6-MMAE ADC SGN-B6A - Anti-integrin Beta-6/MMAE ADC SGN-B6A - SGN B6A - SGN-B6A - SGNB6A - SIGVOTATUG VEDOTIN